9-氨基-N-[3-(二甲基氨基)丙基]-4-吖啶甲酰胺 | 89459-44-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 9-氨基-N-[3-(二甲基氨基)丙基]-4-吖啶甲酰胺
• 中文别名: 2(1H)-喹啉酮,3,4-二氢-6-羟基-1-甲基-3-(甲基氨基)-
• 英文名称: aminacrine
• 英文别名: 9-Amino-N-[3-(Dimethylamino)Propyl]Acridine-4-Carboxamide
• CAS: 89459-44-9
• 化学式: C₁₉H₂₂N₄O
• 分子量: 322.41
• InChiKey: VNWAULKXOPRJEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  71.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  二苯胺-2,2’二羧酸 在 氯化亚砜 、 硫酸 、 氨 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 9-氨基-N-[3-(二甲基氨基)丙基]-4-吖啶甲酰胺
  参考文献：
  名称：

  潜在的抗肿瘤药。43.新型抗肿瘤药二元9-氨基ac啶-4-羧酰胺的合成及生物活性。

  摘要：

  报道了新型抗肿瘤剂N- [2-（二烷基氨基）乙基] -9-氨基ac啶-4-羧酰胺的代表的合成和生物学活性。这类成员是稳定的并且非常易溶于水，具有高水平的体外和体内抗肿瘤活性。这些化合物通过插入与双链DNA紧密结合，但对抗肿瘤活性的要求更为严格。它们主要取决于两个阳离子中心的分离距离，位置和pKa值。对于体内活性，对于C-9 a啶位置附近的亲脂性但不存在亲水性基团以及侧链阳离子部分上的亲脂性和亲水性基团存在显着的体积耐受性。侧链阳离子中心pKa的显着减弱消除了活性，

  DOI：

  10.1021/jm00377a017

文献信息

• CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS
  申请人：Bapat Abhijit S.

  公开号：US20140364595A1

  公开（公告）日：2014-12-11

  The invention provides conjugate-based antifungal or antibacterial prodrugs formed by coupling at least one anti-fungal agent or antibacterial agent with at least one linker and/or carrier. The prodrugs are of formula: (i) (AFA) m -X-(L) n ; (ii) [(AFA) m′ -X] p -L; (iii) AFA-[X-(L) n′ ] q ; or (iv) (AFA) m″ -X, wherein: AFA is an antifungal agent or an antibacterial agent; L is a carrier; X is a linker; m ranges from 1 to 10; n ranges from 2 to 10; m′ is 1 to 10; p is 1 to 10; n′ is 1 to 10; and q is 1 to 10, provided that q′ and n are not both 1; and m″ is 1 to 10. The invention also provides nanoparticles comprising the conjugate-based prodrugs. Additionally, the invention also provides non-conjugated antifungal and antibacterial agents in the form of nanoparticles.

  该发明提供了由至少一种抗真菌剂或抗菌剂与至少一种连接剂和/或载体偶联形成的基于共轭的抗真菌或抗菌前药。这些前药的公式为：(i) (AFA) m -X-(L) n ; (ii) [(AFA) m′ -X] p -L; (iii) AFA-[X-(L) n′ ] q ; 或 (iv) (AFA) m″ -X，其中：AFA是抗真菌剂或抗菌剂；L是载体；X是连接剂；m范围从1到10；n范围从2到10；m′为1到10；p为1到10；n′为1到10；q为1到10，前提是q'和n不同时为1；m″为1到10。该发明还提供了包含基于共轭的前药的纳米粒子。此外，该发明还提供了以纳米粒子形式的非共轭抗真菌和抗菌剂。
• Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
  申请人：Ludwig-Maximilians-Universität München

  公开号：EP2601941A1

  公开（公告）日：2013-06-12

  The present invention relates to beta-O/S/N fatty acids and derivatives thereof, in particular the compounds of formula (I) as described and defined herein, and their pharmaceutical use, including their use in the treatment or prevention of bacterial as well as protozoan infections, in particular the treatment or prevention of infections with Gram-positive and/or Gram-negative bacteria and infectious diseases caused by and/or related to Gram-positive and/or Gram-negative bacteria. The invention further relates to the use of these compounds for preventing or eliminating biofilms.

  本发明涉及beta-O/S/N脂肪酸及其衍生物，特别是如本文所述和定义的公式(I)化合物，及其医药用途，包括用于治疗或预防细菌以及原生动物感染，特别是治疗或预防革兰氏阳性细菌和/或革兰氏阴性细菌引起的感染和传染病以及与之相关的感染和传染病。该发明还涉及这些化合物用于预防或消除生物膜。
• [EN] BETA-O/S/N FATTY ACID BASED COMPOUNDS AS ANTIBACTERIAL AND ANTIPROTOZOAL AGENTS<br/>[FR] COMPOSÉS À BASE DE BÊTA-O/S/N ACIDES GRAS EN TANT QU'AGENTS ANTIBACTÉRIENS ET ANTI-PROTOZOAIRES
  申请人：UNIV MUENCHEN L MAXIMILIANS

  公开号：WO2013083724A1

  公开（公告）日：2013-06-13

  The present invention relates to beta-O/S/N fatty acids and derivatives thereof, in particular the compounds of formula (I) as described and defined herein, and their pharmaceutical use, including their use in the treatment or prevention of bacterial as well as protozoan infections, in particular the treatment or prevention of infections with Gram-positive and/or Gram-negative bacteria and infectious diseases caused by and/or related to Gram-positive and/or Gram-negative bacteria. The invention further relates to the use of these compounds for preventing or eliminating biofilms.

  本发明涉及β-O/S/N脂肪酸及其衍生物，特别是如本文所述和定义的公式(I)化合物，以及它们的医药用途，包括用于治疗或预防细菌以及原生动物感染，尤其是治疗或预防革兰氏阳性菌和/或革兰氏阴性菌感染以及由革兰氏阳性菌和/或革兰氏阴性菌引起的传染病。本发明进一步涉及使用这些化合物来预防或消除生物膜。
• Quinoline derivatives
  申请人：SUMITOMO PHARMACEUTICALS COMPANY, LIMITED

  公开号：EP0268871A1

  公开（公告）日：1988-06-01

  Quinoline derivatives of the formula, wherein R1, R2, R3 and R4 are each hydrogen or one of a specific range of substituents, is one of a specific range of cyclic groups, and are useful as pharmaceuticals such as anti-senile dementia. They may be prepared by synthetic routes analogous to those described in the literature for preparing known compounds.

  喹啉衍生物的公式，其中R1、R2、R3和R4各自是氢或特定范围内的一个取代基，是一个特定范围内的环状基团，并且可用作抗老年痴呆症等药物。它们可以通过与文献中描述的已知化合物相似的合成路线来制备。
• Remote detection of substance delivery to cells
  申请人：Drummond C. Daryl

  公开号：US20050112065A1

  公开（公告）日：2005-05-26

  The present invention provides for the development of endocytosis-sensitive probes, and a remote method for measuring cellular endocytosis. These probes are based on the reduced water permeability of a nanoparticle or liposomal delivery system, and inherent degradability or disruption of barrier integrity upon endocytosis. The invention also provides for liposomes having combined therapeutic and diagnostic utilities by co-encapsulating ionically coupled diagnostic and therapeutic agents, in one embodiment, by a method using anionic chelators to prepare electrochemical gradients for loading of amphipathic therapeutic bases into liposomes already encapsulating an imaging agent. The invention provides for imaging of therapeutic liposomes by inserting a lipopolymer anchored, remotely sensing reporter molecules into liposomal lipid layer. The invention allows for an integrated delivery system capable of imaging molecular fingerprints in diseased tissues, treatment, and treatment monitoring.

  本发明提供了一种用于开发内吞敏感探针的方法，以及一种测量细胞内吞的远程方法。这些探针基于纳米颗粒或脂质体递送系统的降低水透性，以及内吞时固有的可降解性或屏障完整性破坏。该发明还提供了一种具有联合治疗和诊断功能的脂质体，通过共包埋离子耦合的诊断和治疗剂，其中一种实施方式是使用阴离子螯合剂的方法，为脂质体内已包埋成像剂的脂质体加载两性治疗碱。该发明通过将脂质体脂质层插入脂质聚合物锚定的远程感测报告分子来成像治疗脂质体。该发明允许集成递送系统成像疾病组织中的分子指纹，治疗和治疗监测。